Zydus Lifesciences informs about acquisition

04 May 2024 Evaluate

Zydus Lifesciences has informed that, Sentynl Therapeutics Inc., USA, a wholly owned subsidiary (‘Sentynl’) of the Company has acquired worldwide proprietary rights to Zokinvy® (lonafarnib) from Eiger Biopharmaceuticals Inc., USA (‘Seller’), pursuant to an asset purchase agreement (‘APA’), adding to portfolio of biopharmaceuticals for rare and ultra-rare diseases. Zokinvy® is approved in the U.S. (2020), European Union and Great Britain (2022), and Japan (2024) for the treatment of Progeria, a collection of ultra-rare, fatal, genetic premature aging diseases that accelerate mortality in young patients. Necessary details as stipulated under regulation 30 of the Listing Regulations read with para 5 of Part II of the SEBI Circular dated July 13, 2023 are provided in Annexure- ‘1’.

The above information is a part of company’s filings submitted to BSE.


Zydus Lifesciences Share Price

916.55 -5.45 (-0.59%)
12-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1825.00
Dr. Reddys Lab 1318.75
Cipla 1325.25
Zydus Lifesciences 916.55
Lupin 2356.85
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×